Abstract:Background: Acquired, somatic TP53 mutations leading to loss of p53 tumor suppressive functions are the most common genomic alteration across many cancer types. Breast cancer (BC) is the most common malignancy in females, and 50-75% of estrogen receptor (ER)-negative BC (with or without HER2 amplification) and 10-15% of ER+ BC acquire TP53 alterations. Pathogenic germline variants (PGVs) in TP53 occur in approximately 1:5000 people and lead to the Li Fraumeni Syndrome (LFS) in which individuals have an up to 90% risk of developing cancer over their lifetimes. The most common cancer in females with LFS is BC which occurs at a median age of onset of 30-35, nearly 30 years younger than sporadic BC. The distribution of BC subtypes is significantly different in LFS-BC patients compared to sporadic BC, with over half of LFS-BC being HER2+ BC and over 90% being ER+. The characteristics of LFS-BC, namely early onset and predominance of HER2+ disease, suggest different tumorigenesis mechanisms compared to sporadic breast cancer that may have implications for early detection, interception and treatment. Patients and Methods: We performed deep phenotyping on 93 LFS patients with 130 LFS-BC compared to 198 control patients with 209 nonLFS-BC. Controls were defined as having BC diagnosed age<50 and negative germline cancer susceptibility gene testing. We obtained clinical cases and/or blocks for histopathological analysis. DNA and RNA was extracted from available FFPE tumor blocks and analyzed using a targeted capture panel with copy number backbone-based DNA sequencing and RNAseq of ribosomal RNA depleted total RNA. A subset of LFS-BC underwent whole genome sequencing. Finally, slides underwent both single and multiplex immunohistochemistry (IHC) of immune markers. This series includes results of 22 LFS-BC, including seven cases of LFS ductal carcinoma in situ (LFS-DCIS) and 15 invasive ductal carcinomas (LFS-IDC). In addition, matched germline blood for all cases and surrounding (n=15) and/or contralateral (n=11) normal was analyzed. Finally, 27 non-LFS early onset breast cancer controls with matched blood normal were analyzed by the same pipeline. Results were also compared to sporadic BC from The Cancer Genome Atlas (TCGA). Results: Of the 137 adult women in our LFS cohort, 93 (68%) had developed at least one BC, with a total of 110 LFS-BC. The prevalence of BC in our cohort was nearly identical to the prevalence in the National Cancer Institute (NCI) public LFS database (69% of 698 females, p=0.82). The median (IQR) age of first BC diagnosis in our cohort was 36 (29,45) years, similar to the public cohort with a median (IQR) of 31 (27,38) years at first BC diagnosis. Of the 93 adult BC patients in our LFS cohort, 60 (64%) had developed synchronous or metachronous bilateral BC. In contrast, only 36 (18%) of the early-onset nonLFS-BC control cohort developed more than one BC (p<0.0001). LFS-BC was more commonly HER2+ compared nonLFS-BC (51% vs 20%, p 50%) was seen in the majority of tumors from patients with missense mutations; whereas no protein expression (<1%, null pattern) was seen in majority of tumors from carriers of large exonic deletion, truncating, and splicing mutations in TP53. Using p53 IHC and sequencing results, we found evidence of biallelic loss of TP53 (fully mutant p53) in 21 of 22 (95%) LFS-BC, two of 15 surrounding normal (13%) and no contralateral normal breast tissue. Nearly all LFS-BC underwent biallelic loss of TP53 via focal copy neutral or deletion loss of heterozygosity (89%) or a somatically acquired TP53 mutation (9%). No recurrent oncogenic variants were identified except ERBB2 (HER2) copy number amplification. In contrast, recurrent oncogenic alterations in PIK3CA, GATA3 and MAP3K1 were seen in early onset nonLFS-BC, similar to sporadic BC in TCGA. Compared to nonLFS-BC, LFS-BC had lower or similar tumor mutational burden, copy number burden and aneuploid chromosome arm number. LFS-BC were instead marked by elevated focal segments of loss of heterozygosity (LOH) and allelic imbalance. Accordingly, copy number signature analysis from whole genome sequencing showed nearly -Abstract Truncated-

Somatic mutations in early onset luminal breast cancer

The clinical features of breast cancer in young patients

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer

Early-onset breast cancer: a look from molecular biology

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Breast Cancer in Young Women: Is It Different? A Single-Center Retrospective Cohort Study

Luminal breast epithelial cells from wildtype and mutation carriers harbor copy number alterations commonly associated with breast cancer

Genomic aberrations in young and elderly breast cancer patients

Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger

Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers

Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors

High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer

Breast cancer in an 18-year-old female: A fatal case report and literature review

Abstract 3354: Capturing tumor heterogeneity to personalize therapy in young patients with hormone receptor positive breast cancer

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Abstract NG02: Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

Clinical Characteristics of Different Molecular Subtypes of Breast Cancer in Young Patients

Luminal B Subtype: a Key Factor for the Worse Prognosis of Young Breast Cancer Patients in China.